Does UPMC Health Plan Cover Forteo? A Woman's Guide to Teriparatide Insurance Coverage

What Is Forteo and Why Do Women Need It?

Forteo is the brand name for teriparatide, a synthetic fragment of human parathyroid hormone. Injected daily, it stimulates new bone formation rather than simply slowing bone loss, which makes it a different class of drug from the bisphosphonates most women try first. The FDA approved teriparatide in 2002 specifically for postmenopausal women with osteoporosis at high risk for fracture.

Bone loss is not gender-neutral. Women lose bone at a rate of 1 to 3 percent per year during the first five years after menopause because estrogen normally suppresses the bone-resorbing cells called osteoclasts. When estrogen drops, those cells run unchecked, and trabecular bone, the spongy inner lattice most vulnerable to vertebral fractures, thins fastest.

Who Gets Prescribed Forteo?

Teriparatide is reserved for women with:

• A T-score of <-2.5 with one or more fragility fractures
• A T-score of <-3.5 even without a prior fracture
• Severe or multiple vertebral fractures regardless of T-score
• Documented intolerance to or treatment failure on bisphosphonates

The National Osteoporosis Foundation / BHOF clinical practice guide and ACOG Committee Opinion 129 both position anabolic agents including teriparatide as appropriate for high-fracture-risk patients who have not responded to antiresorptive drugs.

Life-Stage Context: When Osteoporosis Becomes Urgent

Perimenopause. Bone loss accelerates in the two to three years before the final menstrual period, a phase many women do not associate with skeletal risk. A DEXA scan at this stage can catch early loss before it becomes severe.

Postmenopause. This is the primary window for Forteo prescriptions. Women who have already fractured, or whose T-scores fall into severe range after several years on a bisphosphonate, are the most common candidates.

Younger women with secondary osteoporosis. Women with anorexia nervosa, long-term glucocorticoid use, premature ovarian insufficiency, or inflammatory bowel disease can develop severe osteoporosis before age 50. In these cases, UPMC Health Plan coverage criteria may be applied differently, and documentation of the underlying cause is essential for prior authorization.

How UPMC Health Plan Formularies Work

UPMC Health Plan is a Pittsburgh-based regional insurer offering commercial, Medicare Advantage (Community HealthChoices), Children's Health Insurance Program, and Medicaid managed-care products. Each product line maintains its own drug formulary, which means coverage for Forteo is not identical across all UPMC plans.

Commercial Plans

On UPMC Health Plan commercial formularies, Forteo is typically listed as a Specialty drug (Tier 4 or Tier 5). Specialty-tier cost sharing commonly runs 20 to 30 percent coinsurance after deductible, which on a drug with a list price of approximately $3,000 to $3,500 per month can produce significant out-of-pocket exposure even with insurance.

Medicare Advantage Plans

Medicare Part D formularies are subject to CMS rules, and specialty-tier cost sharing is capped in the catastrophic phase. However, the prior-authorization criteria on Medicare Advantage plans often mirror commercial criteria: documented T-score, prior fracture, and documented bisphosphonate trial or contraindication.

Medicaid / CHIP

Pennsylvania Medicaid (Medical Assistance) covers teriparatide but typically applies step-therapy requirements identical to or stricter than commercial plans. UPMC for You, the insurer's Medicaid product, follows the Pennsylvania Department of Human Services preferred drug list.

Prior Authorization: What UPMC Typically Requires

Prior authorization (PA) for Forteo on UPMC Health Plan products generally includes documentation of the following:

1. A current DEXA report with T-scores at the lumbar spine and/or total hip
2. A diagnosis of osteoporosis (T-score <-2.5 or fragility fracture history)
3. Evidence of high fracture risk (FRAX score, prior fracture, or T-score <-3.5)
4. Documented trial of at least one bisphosphonate at an adequate dose for at least 12 months, OR a documented clinical reason why bisphosphonate therapy is contraindicated or not tolerated (e.g., esophageal disease, renal impairment with GFR <35 mL/min, documented bisphosphonate-related osteonecrosis of the jaw)
5. Prescriber attestation that cumulative teriparatide use will not exceed 24 months per the FDA-labeled lifetime limit

Your prescriber, typically your OB-GYN, reproductive endocrinologist, or internist with a specialty interest in bone health, submits the PA request. Having all five documentation elements ready before submission significantly reduces the chance of an initial denial.

What Happens If the PA Is Denied?

A denial is not the end of the road. You have the right to:

• Appeal at the plan level. Your prescriber can submit a peer-to-peer review with a UPMC medical director. Success rates for peer-to-peer reviews for specialty drugs in osteoporosis are not publicly reported by UPMC, but appeals supported by full clinical documentation and a letter from your physician carry substantially more weight than the initial submission alone.
• Request an expedited appeal if your clinician certifies that waiting for a standard review would seriously jeopardize your health.
• File an external appeal with the Pennsylvania Insurance Department if the internal appeal is denied.

The WomanRx Prior-Authorization Readiness Checklist for Forteo, developed with our editorial board, identifies the five most common reasons UPMC denies Forteo PAs: missing DEXA report date (must be within the past 24 months), missing FRAX score, absent documentation of bisphosphonate side effects, prescriber not noting the 24-month cumulative limit, and missing serum calcium and renal function labs. Having these five items in order before your prescriber submits can prevent the most common denial triggers.

Cost Assistance Programs When Coverage Falls Short

Even with insurance, the specialty-tier cost share can be prohibitive. Several options exist for women whose plans cover Forteo but leave a large copay.

Eli Lilly Patient Assistance

Eli Lilly, the manufacturer of Forteo, operates the Lilly Cares Foundation Patient Assistance Program, which may provide Forteo at no cost to patients who meet income requirements (typically at or below 400 percent of the federal poverty level) and who lack adequate coverage.

Lilly Insulin Value Program / Forteo Savings Card

For commercially insured patients who do not qualify for full assistance, Lilly has historically offered a savings card that reduces monthly out-of-pocket costs. As of the publication date of this article, eligibility excludes patients with Medicare or Medicaid. Your pharmacist or your prescriber's office can confirm current card availability and whether your specific UPMC commercial plan qualifies.

State Pharmaceutical Assistance Programs

Pennsylvania's PACE and PACENET programs assist older Pennsylvanians with drug costs, including specialty drugs. PACENET income limits as of 2024 are $33,500 for single individuals and $41,500 for couples, per the Pennsylvania Department of Aging. These programs wrap around Medicare Part D and can substantially reduce specialty-tier exposure.

Biosimilar Teriparatide

The FDA approved the first teriparatide biosimilar, Tymlos (abaloparatide) is a related but distinct drug. A true teriparatide biosimilar, Bonsity (teriparatide injection, Alvogen), was approved in 2021. Biosimilars typically carry lower list prices, and UPMC Health Plan may place them on a lower tier than brand-name Forteo. Ask your prescriber whether Bonsity is an option for you and whether UPMC's formulary favors it over the brand.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

Forteo is contraindicated in pregnancy. Animal studies showed that teriparatide caused skeletal abnormalities in offspring at doses producing systemic exposure comparable to the human therapeutic dose, as described in the FDA prescribing information. Human pregnancy data are insufficient to establish safety, and no adequate well-controlled studies exist in pregnant women. The drug should be stopped immediately if pregnancy occurs during treatment, and the treating clinician should be notified at once.

Contraception requirement. Any woman of reproductive potential who is prescribed Forteo should use reliable contraception throughout the treatment period. This is especially relevant for women in perimenopause who may not have reached 12 months of amenorrhea and who retain residual fertility. Do not assume perimenopause means you cannot conceive; ovulation can occur unpredictably until menopause is confirmed.

Lactation. It is not known whether teriparatide is excreted in human milk. Because of the potential for serious adverse reactions in a nursing infant, the manufacturer advises against use during breastfeeding. Women who are postpartum and breastfeeding and who have severe postpartum osteoporosis, a rare but documented condition, should discuss the risk-benefit balance with a specialist before starting any anabolic bone agent. ACOG and the National Osteoporosis Foundation do not currently provide specific guidance on teriparatide in lactating women, reflecting the evidence gap.

Trying to conceive. Forteo is not indicated and not safe in this population. Women with premature ovarian insufficiency who develop severe osteoporosis and who wish to pursue future pregnancy should discuss alternative bone-protective strategies (low-dose estrogen, calcium, vitamin D optimization) with a reproductive endocrinologist.

Sex-Specific Pharmacology of Teriparatide

Women respond to teriparatide somewhat differently than men, though most key trial data come from postmenopausal women, which is one of the few areas of bone drug research where the primary trial population is female.

The landmark Fracture Prevention Trial (FPT) enrolled 1,637 postmenopausal women with prior vertebral fractures. After a median of 21 months, teriparatide 20 mcg/day reduced new vertebral fractures by 65 percent and nonvertebral fractures by 53 percent compared to placebo. Lumbar spine BMD increased by a mean of 9.7 percent. These are the foundational numbers behind every insurance coverage policy for this drug.

Cycle and Hormonal Status

Teriparatide does not interact with endogenous estrogen in a well-studied pharmacokinetic sense, but hormonal status shapes the baseline on which the drug works. Postmenopausal women with lower estrogen have greater osteoclastic activity, and the anabolic signal from teriparatide competes with a more active resorptive environment. This is why sequential therapy (teriparatide followed by an antiresorptive like denosumab or zoledronic acid) is strongly recommended by The Menopause Society to consolidate the BMD gains made during the 24-month anabolic course. Stopping teriparatide without transitioning to an antiresorptive leads to rapid bone loss that can erase much of the benefit within 12 to 18 months.

PCOS and Secondary Osteoporosis

Women with polycystic ovary syndrome (PCOS) who have chronic oligo-ovulation and low estrogen exposure over reproductive years may have lower peak bone mass by the time they reach midlife. If they also have other risk factors such as low BMI, smoking, or long-term hormonal suppression, their fracture risk at perimenopause can exceed that of normally cycling peers. Teriparatide has not been studied specifically in women with PCOS-related osteoporosis, representing a clear evidence gap.

Who This Treatment Is Right For, and Who Should Look at Other Options

Teriparatide is most appropriate for you if:

• You are postmenopausal with a T-score of <-2.5 and have already fractured
• You have tried a bisphosphonate for at least 12 months and your BMD continued to decline or you fractured on therapy
• You cannot tolerate bisphosphonates due to upper GI disease, severe renal impairment, or documented hypersensitivity

Teriparatide is not the right choice if:

• You are pregnant or trying to conceive
• You have a history of bone cancer, Paget's disease of bone, unexplained alkaline phosphatase elevation, or prior radiation therapy to the skeleton (these are FDA contraindications per the prescribing information)
• You have hypercalcemia
• Your fracture risk is moderate rather than high, in which case a bisphosphonate or denosumab is likely more appropriate and far easier to get covered by any insurer

Younger women with secondary causes. If you are under 45 and your osteoporosis is driven by an identifiable secondary cause (celiac disease, inflammatory bowel disease, glucocorticoid use), addressing the underlying cause and optimizing calcium and vitamin D should precede the decision about Forteo. Insurance coverage criteria are harder to meet in this group because the clinical evidence base for teriparatide in premenopausal women is thinner than in the postmenopausal population.

What the Clinical Evidence Gap Means for You

The evidence supporting teriparatide is notably stronger in postmenopausal women than in any other group, which is relatively unusual in clinical medicine. However, this means data are genuinely thin in:

• Premenopausal women with secondary osteoporosis
• Women under glucocorticoid suppression for autoimmune conditions
• Women with PCOS-related bone loss
• Postpartum women with pregnancy-associated osteoporosis

The ACOG osteoporosis committee opinion acknowledges that management of osteoporosis in premenopausal women "requires individualized decision-making" and that randomized trial data in this group are scarce. When your prescriber says the evidence for your situation is less clear, that is an honest and accurate statement, not a reason to dismiss your concerns.

Practical Steps to Get Forteo Covered by UPMC Health Plan

1. Get a current DEXA scan. Results must typically be within 24 months. Ask your clinician to order one with both lumbar spine and bilateral hip measurements.
2. Calculate your FRAX score. Your prescriber can do this using the WHO FRAX tool. A 10-year major osteoporotic fracture probability above 20 percent or hip fracture probability above 3 percent meets the National Bone Health Alliance threshold for pharmacotherapy.
3. Document your bisphosphonate trial. If you tried alendronate, risedronate, or another bisphosphonate, make sure pharmacy fill history and any side-effect notes are in your chart. If you could not tolerate it, ask your clinician to document the specific adverse effect.
4. Have your prescriber submit the PA with all supporting documentation at once. Incomplete submissions are the single most common cause of delay.
5. Call UPMC Health Plan member services at the number on the back of your insurance card to confirm the current formulary status of Forteo and the specific PA criteria in effect for your plan year.
6. Ask about Bonsity (the biosimilar) if brand-name Forteo is denied or placed at a higher tier; your prescriber can request a formulary exception or simply switch the prescription.

How Long Does Coverage Last?

The FDA label for teriparatide limits use to 24 months cumulative over a lifetime. Most UPMC Health Plan prior authorizations are approved in 12-month increments, with renewal requiring documentation that treatment is continuing appropriately and that the 24-month cap has not been reached. After you complete your course of teriparatide, your clinician should start an antiresorptive drug, most commonly denosumab (Prolia) or a bisphosphonate. That transition therapy will itself require prior authorization, so plan ahead.